Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28020820 | 0.92 | HTR6 (0.38) | SOS1SOS2 | |
| SCHEMBL2800752 | 0.92 | SOS1 (0.34) | SOS1SOS2 | |
| SCHEMBL27971606 | 0.90 | HTR6 (0.37) | SOS1SOS2 | |
| Water SCHEMBL28191062 | 0.88 | HTR6 (0.36) | SOS1SOS2 | |
| SCHEMBL13534531 | 0.71 | HTR6 (0.38) | — | |
| SCHEMBL10072967 | 0.71 | HTR6 (0.38) | — | |
| SCHEMBL1120435 | 0.69 | — | — | |
| Ammonia Solution, Strong SCHEMBL28541804 | 0.68 | — | — | |
| Iodide SCHEMBL22031615 | 0.67 | SOS1 (0.52) | SOS1SOS2 | |
| Hydrochloric Acid SCHEMBL1992388 | 0.67 | SOS1 (0.52) | SOS1SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3666774-B1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS JIANGSU LTD (CN) | 2022-05-11 | — | — | EP | disclosed |
| US-11319323-B2 | Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20210147424-A1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2021-05-20 | — | — | US | disclosed |
| EP-3666774-A1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147424-A1 | 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR | CDK1, CDKL1, CDK2 | SOS1 2155/4885SOS2 3124/4885 |
| US-11319323-B2 | Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors | CDK1, CDK2, CDK3 | SOS1 2138/4885SOS2 2883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.